Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

Biotechnology

Healthcare
$17.73 +3.01%

+$0.81 today

Market cap
$1.81B
Beta
0.38
P/E (TTM)
-4.6
EPS (TTM)
-$6.06
52W Low $18.29High $42.37

Volume 5.16M

Average 1.81M

RARE EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Ultragenyx Pharmaceutical Inc.NASDAQ: RARE

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$155M, compared with -$126.44M a year earlier. Trailing-twelve-month EBITDA was -$503.35M.

Context

  • EBITDA amounted to 70.4% of revenue in FY2025, down 13.3 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 14 analysts of -$18.52M (+96.1%) for the fiscal year ending Dec 2026, a step up from the -1.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$155M-54.7% QoQ
Last fiscal yearDec 2025
-$474M-1.1% YoY
LTMMar 2026
-$503.35M-11.9% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.6%-5.9%+16.6 pp
1 year-1.1%+96.1%+97.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(474M) USD
Year-over-year change
-1.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How RARE compares with its peers on the latest reported figures

  • RARE's LTM Mar 2026 EBITDA of -$503.35M is the 9th highest of the 11 companies compared; the peer median is -$146.28M.
  • Its year-over-year change of -11.9% is the 8th highest of 11, against a peer median of +5.7%.
  • EBITDA amounts to 75.2% of revenue for RARE, versus a peer median of 185.2%.
RARE Competitors Peer median
EBITDA for RARE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PTCTPTC Therapeutics, Inc.LTM Jun 2026$173.52M -79.4%—17.2%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$73.43M +298.8%—505.0%
MREOMereo BioPharma Group plcLTM Mar 2026-$39.29M +13.4%—7858.4%
MGTXMeiraGTx Holdings plcLTM Mar 2026-$95.72M +32.5%—120.0%
QUREuniQure N.V.LTM Mar 2026-$129.14M +6.4%—713.8%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-$163.43M +3.9%—185.2%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026-$194.47M +21.0%——
RGNXREGENXBIO Inc.LTM Mar 2026-$229.35M -87.3%—261.2%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-$503.35M -11.9%—75.2%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026-$611.26M +5.0%—85.7%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-$81.69B -10676.6%+29.2%8.0%
Peer median (excluding RARE) -$146.28M+5.7%+29.2%185.2%

Competitors are the stored peer set for RARE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue351.41M363.33M434.25M560.23M673M
Cost of Revenue16.01M28.32M45.21M76.73M109M
Gross Profit335.4M335.01M389.04M483.5M564M
Gross Margin95.4%92.2%89.6%86.3%83.8%
Research & Development497.15M705.79M648.45M697.87M750M
Selling, General & Admin219.98M278.14M309.8M321.61M349M
Operating Expenses717.14M983.93M958.25M1.02B1.1B
Depreciation & Amortization13.24M18.22M26.01M35.54M35M
EBITDA(410.32M)(640.49M)(516.45M)(469M)(474M)
EBITDA Margin-116.8%-176.3%-118.9%-83.7%-70.4%
Operating Income(381.74M)(648.92M)(569.21M)(535.97M)(535M)
Operating Margin-108.6%-178.6%-131.1%-95.7%-79.5%
Interest Income1.93M11.07M26.69M36.51M25M
Interest Expense29.42M43.02M66M63.04M62M
Other Income / Expenses(71.24M)(52.81M)(39.26M)(31.61M)(36M)
Income Before Tax(452.98M)(701.73M)(608.46M)(567.59M)(571M)
Pre-Tax Margin-128.9%-193.1%-140.1%-101.3%-84.8%
Income Tax Expense1.04M5.7M(1.83M)1.6M4M
Net Income(454.03M)(707.42M)(606.64M)(569.18M)(575M)
Net Margin-129.2%-194.7%-139.7%-101.6%-85.4%
EPS (Basic)(6.70)(10.12)(8.25)(6.29)(5.83)
EPS (Diluted)(6.70)(10.12)(8.25)(6.29)(5.83)
Weighted Avg Shares67.8M69.91M73.54M90.54M98.6M
Weighted Avg Shares (Diluted)67.8M69.91M73.54M90.54M98.6M

Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

Intrinsic Alpha fair value

Locked

Current Price

$17.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.